Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Express Scripts
US Army
AstraZeneca
Federal Trade Commission
Cantor Fitzgerald
Moodys
Chinese Patent Office
McKesson

Generated: May 25, 2018

DrugPatentWatch Database Preview

LIVOSTIN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Livostin patents expire, and when can generic versions of Livostin launch?

Livostin is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in LIVOSTIN is levocabastine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the levocabastine hydrochloride profile page.
Summary for LIVOSTIN
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 17
Patent Applications: 2,261
DailyMed Link:LIVOSTIN at DailyMed
Drug patent expirations by year for LIVOSTIN
Synonyms for LIVOSTIN
(-)-trans-1-(cis-4-Cyano-4-(p-fluorophenyl)cyclohexyl)-3-methyl-4-phenylisonipecotic acid monohydrochloride
(+-)-trans-1-(cis-4-Cyano-4-(p-fluorophenyl)cyclohexyl)-3-methyl-4-phenylisonipecotic acid
(+-)-trans-1-(cis-4-Cyano-4-(p-fluorophenyl)cyclohexyl)-3-methyl-4-phenylisonipecotic acid.
(3S,4R)-1-(4-Cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenylpiperidine-4-carboxylic acid
(3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-piperidine-4-carboxylic acid
(3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid
(3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid hydrochloride
(3S,4R)-1-[cis-4-Cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic Acid Hydrochloride
(3S,4R)-Cabastine Hydrochloride
[3S-[1(cis),3|A,4|A]]-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic acid
[3S-[1(cis),3|A,4|A]]-1-[4-Cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecarboxylic Acid Monohydrochloride
1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-4-piperidinecarboxylic acid
124XMA6YEI
4-Piperidinecarboxylic acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, (3S-(1(cis),3alpha,4beta))-
4-Piperidinecarboxylic acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, monohydrochloride, (-)-(1(cis),3alpha,4beta)-
4-Piperidinecarboxylic acid, 1-(cis-4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, monohydrochloride, (3S,4R)-
79516-68-0
79516-68-0 (Parent)
79547-78-7
79547-78-7 (hydrochloride)
AB00514704
AB00514704-06
AC1L1GWO
AC1L1GWR
AC1Q1SRD
AJ-23611
AK129788
AKOS016013998
AN-6364
BDBM50019405
Bilina
BPBio1_001382
BRD-K33453211-003-03-2
BSPBio_001257
C-22070
C26H29FN2O2
C26H29FN2O2.HCl
Cabastine [INN]
Cabastinum
CAS-79547-78-7
CCG-221039
CHEBI:135679
CHEBI:31777
CHEBI:92584
CHEMBL1237102
CHEMBL1615438
D01717
D08117
D08SEI
DB01106
DSSTox_CID_25508
DSSTox_GSID_45508
DSSTox_RID_80921
DTXSID1048548
DTXSID9045508
FT-0630869
GTPL1586
H68BP06S81
HE389796
HMS1571O19
Levocabastin
Levocabastina
Levocabastina [Spanish]
levocabastine
Levocabastine (INN)
Levocabastine [INN:BAN]
Levocabastine for system suitability 2, European Pharmacopoeia (EP) Reference Standard
Levocabastine HCl
LEVOCABASTINE HYDROCHLORIDE
Levocabastine hydrochloride (JAN/USAN)
Levocabastine hydrochloride [USAN:USP]
Levocabastine hydrochloride [USAN]
Levocabastine hydrochloride, >=99% (HPLC), solid
Levocabastine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Levocabastine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Levocabastinum
Levocabastinum [Latin]
Levocobastine
Levophta
Levostin
Livostin (TN)
LS-114668
LS-177481
MLS002154116
MolPort-044-561-796
NCGC00016939-01
NCGC00179240-01
NCGC00179240-02
NCGC00179240-04
Prestwick0_001039
Prestwick1_001039
Prestwick2_001039
Prestwick3_001039
R 50,547
R 50547
R-50547
R50547
SCHEMBL152978
SCHEMBL4577
SCHEMBL99969
SCHEMBL99970
SMR001233423
SPBio_003108
Tox21_110695
Tox21_110695_1
UNII-124XMA6YEI
UNII-COU3RRH769 component ZCGOMHNNNFPNMX-KYTRFIICSA-N
UNII-H68BP06S81
ZINC100089496
ZINC586239

US Patents and Regulatory Information for LIVOSTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis LIVOSTIN levocabastine hydrochloride SUSPENSION/DROPS;OPHTHALMIC 020219-001 Nov 10, 1993 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Julphar
Cipla
US Department of Justice
Medtronic
Chinese Patent Office
Mallinckrodt
Healthtrust
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.